Research

#AstraZeneca #Clinical trials #Covid-19 #Moderna #Pfizer #Research

Behind the UK Cov-Boost trial

The UK government has begun the Cov-Boost clinical trials for a booster coronavirus vaccine in a bid to test its effectiveness against the new variants of the virus. As part of the trial, seven vaccines ordered by the UK government will be tested on thousands of volunteers at random in… Read More

#Covid-19 #Exclusive Content #News

#Biotherapeutics #Drug development #Nanomedicine / nanotechnology #Research

New platform uses nanothechnolgy to deliver therapeutics

The Infection Innovation Consortium (iiCON) has launched The Nanotherapeutics Hub, based at the University of Liverpool in the UK, part of Liverpool’s Centre of Excellence for Long-acting Therapeutics (CELT). The agreement will see The Nanotherapeutics Hub work with iiCON to support companies looking to develop nanotherapeutics to combat infectious diseases… Read More

#Editor's Choice #News

#AI #AI / data analytics / healthtech / informatics #Drug candidates #Drug design #Drug discovery #Research

AI accelerates discovery of small molecule drug candidates

Exscientia has entered into a collaboration agreement with Bristol-Myers Squibb Company. The collaboration will use AI to accelerate the discovery of small molecule therapeutic drug candidates in multiple therapeutic areas, including oncology and immunology. This expanded collaboration builds upon Exscientia’s existing collaboration with Bristol Myers Squibb that was initiated in… Read More

#News

#Aspergillosis #Nanomedicine / nanotechnology #Research

How nanoparticle drug inhalation helps fungal lung infections

Treatment for fungal lung infections could be more efficient when medication is inhaled using nanoparticle technology, according to research from the University of Central Lancashire (UCLan). The early findings of the study published in Springer Nature: Journal of Nanobiotechnology are of particular significance as many people with lung diseases that… Read More

#News

#Drug development #Drug discovery #Malaria #Research

Malaria stopped in its tracks with new drug compound

Researchers at the Francis Crick Institute and the Latvian Institute of Organic Synthesis have designed a drug-like compound which effectively blocks a critical step in the malaria parasite life cycle and are working to develop this compound into a potential first of its kind malaria treatment. While drugs and mosquito… Read More

#News

#Data #Diabetes #GlobalData #Research #Therapeutics

Global diabetes therapeutic market has grown sixfold in last 20 years

According to GlobalData, the diabetes market has gone through significant maturation, attributed to increased innovation and modernisation of therapeutic treatments over the past 20 years. The market has been a lucrative space for drug developers, as the disease is highly prevalent and patient numbers are expected to continue increasing in… Read More

#News

#Clinical trials #Database #Drug development #Research

Clinical trials database will save researchers time and resources

The National Institute for Health Research’s Innovation Observatory (NIHRIO), based at Newcastle University, has launched a comprehensive database of clinical trials as well as FDA-approved medical devices, diagnostics and digital applications. Designed as a free resource, researchers can access information about what research is in progress in their area… Read More

#News

#Cancer research #Drug targets #Immuno-oncology #Oncology #Research #Vaccines

Personalised cancer vaccine 45% effective at targeting tumours

Researchers have developed an effective vaccine that re-engineers cells from a patient’s tumour to target and destroy cancer cells. The results, published in the peer-reviewed Journal of Clinical Oncology, show that 45% of patients treated with an autologous cell vaccine, created from their own cancer cells, had a confirmed anti-tumour… Read More

#News

#Antibodies #Cancer research #Drug development #Research

Flow Eighteen38 reagent antibodies licensed for cancer research

Flow Eighteen38, FairJourney Biologics (FJB) and the Hubrecht Institute are working together to harness the potential of FJB’s proprietary llama naïve libraries to develop antibodies for research tools for the group Hans Clevers. The Clevers group is studying molecular mechanisms of tissue development and cancer of various organs using organoids… Read More

#News

#Biotechnology #Data #Research

Vizgen advances spatial genomics research

Vizgen has released its first freely available dataset, the Vizgen MERFISH Mouse Brain Receptor Map. This is reportedly the first of a series of datasets that will be made available through the company’s new Data Release Program. The MERFISH release is said to mark the first time the research community… Read More

#News

#Biotechnology #Drug development #FDA #Research

The FDA expands lung-on-a-chip collaboration with CN Bio

The US. Food and Drug Administration (FDA) has extended its research collaboration with CN Bio for a further three years. The scope of the research carried out with the FDA’s Center for Drug Evaluation and Research (CDER) has now been broadened to include the exploration of CN Bio’s lung-on-a-chip using… Read More

#News

#Bioscience #Covid-19 #Research

Taconic biosciences launches new Covid-19 mouse model

Taconic Biosciences, providers of animal model solutions for drug discovery, has launched a new Covid-19 mouse model. This human ACE2 (hACE2) transgenic mouse expands Taconic’s Covid-19 research toolkit. In October 2020, Taconic launched its first hACE2 model. The AC70 mouse experiences a lethal response to infection by SARS-CoV-2, the virus… Read More

#Covid-19 #News

#Covid-19 #Research

Covid & ethnic minorities: are there differences in immune response

Oxford Immunotec’s T-SPOT Discovery SARS-CoV-2 kit will be used for T cell testing in a study being carried out in collaboration with researchers at the University of Leicester. The  DIRECT study (Determining the Immune Response in Ethnic minority healthcare workers to Covid-19 infecTion) is recruiting healthcare workers in Leicester for… Read More

#Covid-19 #News

#Bacteria #Drug discovery #Research

‘Last resort’ antibiotic pops bacteria like balloons

Scientists have revealed how an antibiotic of ‘last resort’ kills bacteria. The findings, from Imperial College London and the University of Texas, may also reveal a potential way to make the antibiotic more powerful. The antibiotic colistin has become a last resort treatment for infections caused by superbugs. However, despite… Read More

#News

#Corning Life Sciences #Drug delivery #Drug development #Drug discovery #Gene therapy #Genetics #Genetics / genomes #Life sciences #Research

Process Development in Gene Therapy: Four Things to Know

By John Yoshi Shyu, Ph.D. Corning Life Sciences. Gene therapy – the addition, deletion, or modification of genes in living organisms – has been around, at least in concept, since the 1980s. Gene modification or editing incorporates two main strategies: insertion of novel genetic constructs into existing genes, and gene… Read More

#Exclusive Content #News